<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03256071</url>
  </required_header>
  <id_info>
    <org_study_id>DAC+BUCY</org_study_id>
    <nct_id>NCT03256071</nct_id>
  </id_info>
  <brief_title>Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT</brief_title>
  <official_title>Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, open-label, randomized multicenter study is to evaluate the
      safety and efficacy of low dose decitabine in combination with modified BUCY vs modified BUCY
      as a myeloablative conditioning regimen for high-risk patients with acute myeloid leukemia
      (AML) undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allo-HSCT is the most effective treatment stratagey for high risk acute myeloid leukemia. At
      present, modified BUCY is the standard conditioning regimen for AML undergoing allo-HSCT in
      our institute. However, relapse occured in as high as 30-50% high risk AML patients after
      allo-HSCT. Thus, the best conditioning regimen for this subgroup remains to be optimized. Low
      dose decitabine in combination with chemotherapy have been shown to improve comple remission
      rate of high risk AML patients. To reduce the relapse rate after allo-HSCT, low dose
      decitabine is added in the modified BUCY regimen. In this study, the safety and efficacy of
      low dose decitabine + modified BUCY vs modified BUCY myeloablative conditioning regimens in
      high risk undergoing allo-HSCT are evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>3 year</time_frame>
    <description>time from randomization to the first of reccurrence or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>3 year</time_frame>
    <description>time from randomization to death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>veno-occlusive disease (VOD)</measure>
    <time_frame>3 year</time_frame>
    <description>incidence of veno-occlusive disease (VOD) events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft-versus-host disease (GvHD)</measure>
    <time_frame>3 year</time_frame>
    <description>incidence and severity of acute (aGvHD) and chronic graft-versus-host disease (cGvHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transplant related mortality （TRM）</measure>
    <time_frame>3 year</time_frame>
    <description>cumulative incidence of transplant related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>3 year</time_frame>
    <description>cumulative incidence of relapse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation</condition>
  <condition>Conditioning</condition>
  <arm_group>
    <arm_group_label>Decitabine plus Modified BUCY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Decitabine plus Modified BuCy regimen consisted of decitabine,semustine,cytarabine, busulfan and cyclophosphamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified BUCY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Modified BuCy regimen consisted of semustine,cytarabine, busulfan and cyclophosphamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine plus Modified BUCY</intervention_name>
    <description>Decitabine:20 mg/m²/day on day -14 to -10;
Modified BUCY:
Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.</description>
    <arm_group_label>Decitabine plus Modified BUCY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified BUCY</intervention_name>
    <description>Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.</description>
    <arm_group_label>Modified BUCY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 12 to 60 years.

          -  Diagnosis of high-risk acute myeloid leukemia at the time of transplant. (&quot;High-risk&quot;
             AML features are defined by the following: relapsed or primary refractory AML;
             Secondary AML（AML Secondary to myelodysplastic syndrome(MDS) or treatment-related
             AML); extramedullary leukemia; adverse cytogenetic abnormalities of monosomy 5,
             monosomy 7, or deletion of 5q; or presence of FLT3 positive internal tandem
             duplication (FLT3/ITD+), particularly high allelic ratio.)

          -  Patient must have adequate pre-transplant organ function.

        Exclusion Criteria:

          -  Age &lt;12 or &gt;60 years.

          -  Uncontrolled bacterial, viral, fungal, or other infection before conditioning regimen.

          -  Any other severe concurrent diseases, or have a history of serious organ dysfunction.

          -  Pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Depei Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaowen Tang, MD</last_name>
    <phone>+86-512-67781851</phone>
    <email>xwtang1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Depei Wu, MD</last_name>
    <phone>+86-512-67781851</phone>
    <email>wudepei@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaowen Tang, MD</last_name>
      <phone>+86-512-67781851</phone>
      <email>xwtang1020@163.com</email>
    </contact>
    <investigator>
      <last_name>Depei Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Semustine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

